Signify Bio develops personalized protein therapeutics by engineering signal peptides and leveraging mRNA‑encoded designs to control protein expression. Their platform enables rapid creation of nucleic‑acid‑enabled medicines tailored to individual patients, accelerating the development of targeted treatments.
Funding
$15M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Developing individualized protein therapeutics is hampered by slow design cycles, limited control over protein expression levels, and the inability to rapidly tailor treatments to each patient’s unique biology.
Solution
Signify Bio combines signal peptide engineering with mRNA‑based therapeutic design to create nucleic‑acid‑enabled protein drugs that can be customized for individual patients. The platform uses engineered signal peptides to precisely regulate protein secretion and activity, while mRNA encoding accelerates the design and production of the therapeutic protein. This integrated approach shortens development timelines and enables scalable manufacturing of personalized medicines across multiple disease areas.
Target Audience
Primary customers are pharmaceutical and biotech companies seeking to develop patient‑specific protein therapeutics, as well as clinical research organizations focused on personalized treatment pipelines.
Features
- Signal peptide engineering to modulate protein expression, localization, and secretion dynamics
- mRNA‑encoded therapeutic design for rapid synthesis and iteration of protein candidates
- Integrated workflow that links peptide control with mRNA production to ensure consistent dosing
- Platform architecture supporting fast customization for patient‑specific targets
- Compatibility with existing biomanufacturing processes to facilitate scale‑up